A Study of Chinese Congenital Bicuspid Aortic Valve

NCT06802016 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-02-03

No results posted yet for this study

Summary

Pervious studies indicated that the prevalence of bicuspid aortic valve(BAV) might be higher in China. There is a familial predisposition to the development of BAV. The study analyzed epidemiological data on selected BAV and established a BAV cohort to observe disease progression and treatment outcomes.

Conditions

  • Bicuspid Aortic Valve (BAV)

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Zhengbin Zhu, MD, PhD · Ruijin Hospital

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-18
Primary Completion
2029-12-31
Completion
2035-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06802016 on ClinicalTrials.gov